NCT00005841 is a Phase 1 clinical trial of MART-1 antigen in Intraocular Melanoma, sponsored by University of Southern California.

Who is sponsoring NCT00005841?

NCT00005841 is sponsored by University of Southern California.

What drugs are being tested in NCT00005841?

Interventions in NCT00005841: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, progenipoietin, tyrosinase peptide.

What condition does NCT00005841 study?

NCT00005841 studies Intraocular Melanoma, Melanoma (Skin).

Is NCT00005841 still recruiting?

NCT00005841 is currently terminated. Last updated 20 May 2014.

Last reviewed 2014-05-20 · How we verify

NCT00005841

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 With ProGP for Patients With Resected Stages III and IV Melanoma

Terminated Phase 1 Last updated 20 May 2014

What this trial tests

Phase 1 trial testing MART-1 antigen in Intraocular Melanoma in 15 participants. Terminated before completion.

Timeline

1 June 2000

Primary endpoint
1 December 2000

1 October 2002

Quick facts

Lead sponsor	University of Southern California
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	15
Start date	1 June 2000
Primary completion	1 December 2000
Estimated completion	1 October 2002
Sites	2 locations across United States

Drugs / interventions tested

MART-1 antigen — full drug profile →
gp100 antigen
incomplete Freund's adjuvant — full drug profile →
progenipoietin — full drug profile →
tyrosinase peptide — full drug profile →

Conditions studied

Intraocular Melanoma — all drugs for Intraocular Melanoma →
Melanoma (Skin) — all drugs for Melanoma (Skin) →

Sponsor

University of Southern California

Who can join

18 and older, any sex, with Intraocular Melanoma or Melanoma (Skin). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Vaccine therapy plus filgrastim combined with a specific protein may be a more effective treatment for melanoma. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma that has been completely removed during surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Antigen-specific vaccines for cancer treatment.
Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, et al · · 2014 · cited 109× · PMID 25483639 · DOI 10.4161/21645515.2014.973317
Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.
Basile MS, Mazzon E, Fagone P, Longo A, et al · · 2019 · cited 42× · PMID 31750244 · DOI 10.3389/fonc.2019.01145
Advances and Challenges in Immunotherapy for Metastatic Uveal Melanoma: Clinical Strategies and Emerging Targets.
Grigoruta M, Kong X, Qin Y. · · 2025 · cited 1× · PMID 40725830 · DOI 10.3390/jcm14145137

Verify or expand the search:

Other University of Southern California trials

Trials by the same sponsor.

NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00005841 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern California
Last refreshed: 20 May 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00005841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing